title: In vitro generation of influenza-specific polyfunctional CD4+ T cells suitable for adoptive immunotherapy.
abstract: OBJECTIVE
  Influenza viruses cause potentially fatal respiratory infections in stem cell transplant patients. Specific T cells provide long-lived host adaptive immunity to influenza viruses, and the potential for generating such cells for clinical use was investigated.
  
  
  METHODS
  The inactivated influenza vaccine (Fluvax) approved for human use was used as the antigen source. Monocyte-derived dendritic cells pulsed with Fluvax were used to stimulate autologous peripheral blood mononuclear cells (PBMC) on days 0 and 7. Cells were expanded with interleukin (IL)-2 from day 7 onwards. Cell numbers and phenotype were assessed on day 21. The presence of influenza virus-specific cells was assessed by cytokine production and proliferative responses following restimulation with influenza antigens.
  
  
  RESULTS
  Over 21 days of culture, a mean fold increase of 26.3 in cell number was observed (n = 7). Cultures were predominantly effector and central memory CD4+ cells, and expressed a phenotype characteristic of activated antigen-specific cells capable of B-cell helper function. Cytotoxic CD4+ and CD8+ cells specific for influenza and a high percentage of CD4+ cells specific for each of three influenza viruses targeted by Fluvax (H1N1, H3N2 and Brisbane viruses) were generated. In addition, T cells expanded when restimulated with antigens derived from influenza viruses.
  
  
  CONCLUSIONS
  We have demonstrated a clinically usable method for producing influenza virus-specific T cells that yield high numbers of highly reactive CD4+ cells suitable for adoptive immunotherapy. We propose that reconstructing host immunity through adoptive transfer of influenza virus-specific T cells will reduce the frequency of influenza-related deaths in the period of severe immune suppression that follows stem cell transplantation.
authors.affiliation: Westmead Institute for Cancer Research, Westmead Millennium Institute and Faculty of Medicine, The University of Sydney, NSW, Australia.
authors.forename: Shivashni S
authors.initials: SS
authors.lastname: Gaundar
authors.forename: Emily
authors.initials: E
authors.lastname: Blyth
authors.forename: Leighton
authors.initials: L
authors.lastname: Clancy
authors.forename: Renee M
authors.initials: RM
authors.lastname: Simms
authors.forename: Chun K K
authors.initials: CK
authors.lastname: Ma
authors.forename: David J
authors.initials: DJ
authors.lastname: Gottlieb
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000166:cytology* / Q000276:immunology*; D049109:Cell Proliferation; D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D007252:Influenza Vaccines / Q000627:therapeutic use; D007251:Influenza, Human / Q000276:immunology* / Q000628:therapy; D007376:Interleukin-2 / Q000276:immunology / Q000378:metabolism; D009000:Monocytes / Q000276:immunology; D009975:Orthomyxoviridae / Q000276:immunology; D015164:Vaccines, Inactivated / Q000627:therapeutic use
chemical_list: D016207:Cytokines; D007252:Influenza Vaccines; D007376:Interleukin-2; D015164:Vaccines, Inactivated